The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II neoadjuvant trial of sequential triweekly nanoparticle albumin-bound paclitaxel and cyclophosphamide followed by 5-fluorouracil/epirubicin/ cyclophosphamide in the treatment of operable breast cancer.
Norio Masumoto
No relevant relationships to disclose
Takayuki Kadoya
No relevant relationships to disclose
Ai Amioka
No relevant relationships to disclose
Keiko Kajitani
No relevant relationships to disclose
Akiko Emi
No relevant relationships to disclose
Hideo Shigematsu
No relevant relationships to disclose
Rumi Haruta
No relevant relationships to disclose
Tsuyoshi Kataoka
No relevant relationships to disclose
Kazuo Matsuura
No relevant relationships to disclose
Morihito Okada
No relevant relationships to disclose